Moleko

Moleko is a biotechnology company focused on the discovery and development of next-generation molecular glue degraders to treat serious diseases. Founded by industry veterans with deep expertise in targeted protein degradation, the company utilizes a proprietary platform to identify small molecules that induce novel interactions between E3 ligases and disease-causing proteins. Moleko aims to address "undruggable" targets that are inaccessible to traditional small molecule inhibitors or PROTACs. The company is currently building a robust pipeline of precision medicines primarily focused on oncology and immunology. By leveraging advanced computational and experimental techniques, Moleko seeks to expand the landscape of degradable proteins and improve patient outcomes.